HR-EEG Contribution in Prognostic Evaluation of Language Development in Children With ASD

Launched by ETABLISSEMENT PUBLIC DE SANTÉ BARTHÉLEMY DURAND · Oct 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how certain brain activity (measured through a test called EEG-HR) can help predict language development in young children with Autism Spectrum Disorder (ASD). The researchers will follow children aged 3 to 4.5 years over four years to see how their language skills develop. They will have regular check-ups each year, where they will participate in various tests and have their brain activity recorded. The study will include two groups: one with children diagnosed with ASD who have trouble with language, and another group of non-ASD children who do not have language delays, matched by age and gender.

To be eligible for the study, children must be between 3 and 4.5 years old and have consent from their parents. The children with ASD must have a diagnosis according to established criteria and show a lower level of expressive language skills. The control group children must be similar in age and gender to those in the ASD group but must not have any language delays or other significant health issues. It's important to note that children with serious health conditions that could affect the brain activity readings cannot participate. Overall, this study aims to better understand the connection between brain activity and language development in children with ASD, which may help in future treatment and support strategies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • For all participants
• • Child aged from 3 years to 4 years and half at inclusion.
• • Information delivered and no parental objection for study participation.
• • For ASD group
• • Diagnosis of ASD according to DSM-V criteria.
• • Expressive language level \< 27 months regarding on IDE scale.
• • For Control group - Matched on age (at +/- 3 months) and gender to ASD group participants.
• Exclusion Criteria:
• • For all participants
• • Any illness or treatment that could significantly alter EEG-HR recording (epilepsy, anti-epileptic treatment, psychotropic drugs...).
• • Major hearing or vision disorders.
• • For ASD group
• • - Severe and characterised neurological pathology other than ASD
• • For Control group
• • Characterised neurological or psychiatric pathology.
• • Characteristic language delay.